

PERSISTENCE AND COST ANALYSIS OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIASIS

SÁNCHEZ R, ALMIÑANA M, CORTELL C, GARCÍA A, ANTÓN M, JIMÉNEZ A, CORPA B.
 University Clinical Hospital, Valencia, Spain


BACKGROUND AND IMPORTANCE

We know that the lack of persistence of the treatment affects its efficacy and can lead to an increase in the dose, which triggers an increase in risk and cost.

AIM AND OBJECTIVES

To determine the persistence of treatment with secukinumab and the cost of persistent treatment in its approved indications: psoriatic arthritis (PsA), ankylosing spondylitis (AS) and psoriasis.

MATERIAL AND METHODS




Descriptive, retrospective observational study, which included adult patients with PsA, AS and psoriasis treated with secukinumab between November 2017 and August 2021. The demographic variables of age and sex were considered. The main variables were the persistence of secukinumab treatment and the annual cost per persistent treatment. Treatment persistence was analyzed using the Kaplan-Meier test for each indication. The cost per persistent treatment was calculated based on the probability of persistence, which was estimated with the **area under the curve** for each of the three curves obtained in the Kaplan-Meier analysis.

RESULTS

We included 138 patients with a mean age of 52.2 ± 13.9 years, of whom 67 (48.6%) were women. The mean persistence of secukinumab treatment in **PsA** was **36.5 (95% CI 30.7-42.2) months**, for **AS** it was **39.7 (95% CI 34.3-45.2) months** and in **psoriasis** it was **40.4 (95% CI 35.1-45.7) months**. A relationship between age, gender, indication, and line of treatment with secukinumab persistence could not be established. Median persistence was not reached for any of the three diagnoses. The annual cost per persistent treatment, calculated based on the probability of persistence, was 11,064€ for PsA, 8,183€ for AS, and 15,420€ for psoriasis.

Disease	TC (€)	CPT (€)	TC calculated based on the PPT (€)	CPT calculated based on the PPT (€)
PsA	519,408	14,840	1,177,865	33,653
AS	526,475	14,229	1,001,672	27,072
Psoriasis	792,674	24,771	1,661,223	51,913
TOTAL	1,838,557	17,678	3,840,760	36,930

TC: Total cost; CPT: Cost per persistent treatment; PPT: Probability of persistence to treatment.



CONCLUSION AND RELEVANCE

Mean secukinumab persistence was higher for psoriasis compared to PsA and AS ($p > 0.05$). The highest annual cost per persistent treatment was for psoriasis. More studies with real-life data and larger sample sizes are needed to establish the factors that play a key role in the persistence of secukinumab treatment.

